XTANDI offers your patients proven efficacy in high-risk nmCRPC and asymptomatic or mildly symptomatic mCRPC, and is generally well tolerated with a well studied safety profile.1-3
1.XTANDI Summary of Product Characteristics, Xtandi NM_SmPC
2. HussainM et al. NEJM. 2018; 378:2465-74.
3. Beer TM et aL. Eur Urol. 2017; 71:151-4.
In case of any suspected adverse events or any safety information associated with Xtandi™, please report immediately to: Pharmacovigilance.ae@astellas.com Or contact the following number: Tel: +966-11-2218300 / +966-11-2218500 Mob: +966-53 7070 557
In case of any medical inquiry, please contact: Medinfo.MiddleEas-sm@astellas.com
Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.
The National Pharmacovigilance Center (NPC)
Fax: +966-11-205-7662 / SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa / Website: https://ade.sfda.gov.sa